Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Precision genome editing in the eye.

Proceedings of the National Academy of Sciences of the United States of America - 27 Sept 2022

Suh Susie, Choi Elliot H, Raguram Aditya, Liu David R, Palczewski Krzysztof

Abstract excerpt

CRISPR-Cas-based genome editing technologies could, in principle, be used to treat a wide variety of inherited diseases, including genetic disorders of vision. Programmable CRISPR-Cas nucleases are effective tools for gene disruption, but they are poorly suited for precisely correcting pathogenic mutations in most therapeutic settings. Recently developed precision genome editing agents, including base editors and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CRISPR and Genetic Engineering
Share to CRISPR-Cas Systems

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Endonucleases

Share to Gene Editing

Share to Mosquito-borne diseases and control

Share to Mutation

Share to Retinal Development and Disorders

Share to Vision Disorders

Source

Open in PubMed Open full text

Identifiers

PMID: 36122230
DOI: 10.1073/pnas.2210104119
PMCID: PMC9522375

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Precision genome editing in the eye.PMID 36122230Read ↗

Gene therapy for inherited retinal diseases: exploiting new tools in genome editing and nanotechnologySemantic proximity Read ↗

The Application of CRISPR/Cas9 for the Treatment of Retinal Diseases.Semantic proximity Read ↗

Base and Prime Editing in the Retina—From Preclinical Research toward Human Clinical TrialsSemantic proximity Read ↗

Future Perspectives of Prime Editing for the Treatment of Inherited Retinal Diseases.Semantic proximity Read ↗

Therapeutic applications of CRISPR /Cas9 gene editing technology for the treatment of ocular diseasesSemantic proximity Read ↗

Ocular delivery of CRISPR/Cas genome editing components for treatment of eye diseasesSemantic proximity Read ↗

Genome-Editing Strategies for Treating Human Retinal DegenerationsSemantic proximity Read ↗

CRISPR Interference-Potential Application in Retinal Disease.Semantic proximity Read ↗

Revolution in Gene Medicine Therapy and Genome TherapySemantic proximity Read ↗

From bench to bedside: Developing CRISPR/Cas-based therapy for ocular diseasesSemantic proximity Read ↗

The application and progression of CRISPR/Cas9 technology in ophthalmological diseasesSemantic proximity Read ↗

CRISPR-Based Genome Editing as a New Therapeutic Tool in Retinal Diseases.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.